testing, 73% were on prednisone (P) with azathioprine, mycophenolate mofetil (MMF), methotrexate or leflunomide. None of the nontransplanted vasculitis patients had detectable plasma BKV. Among 35 patients in group B, 16 were tested for BKV; 5/16 (31%) had detectable virus in plasma at a mean of 6 months after TX (p = 0.002). Most (94%) were on maintenance therapy with MMF, P and tacrolimus. Conclusion: Immunosuppressed patients with GPA/MPA without KTX had no evidence of plasma BKV. However, BKV was common in GPA/MPA patients after KTX, suggesting that replication may be related to differences in immunosuppression, alloimmune activation or differences in host defense mechanisms.
culating anti-neutrophil cytoplasmic autoantibodies (ANCA) are found in 80-94% of these patients, which led to the nomenclature ANCA-associated vasculitis (AAV) [1, 2] . Renal involvement in AAV is common with 25% of patients developing end-stage renal disease (ESRD) and requiring renal transplant [3, 4] .
The introduction of cytotoxic therapy has changed the prognosis of these diseases from an invariably fatal disease to a manageable chronic illness with a relapsing course. Therapy consists of a staged treatment approach involving two phases: (1) remission induction with aggressive immunosuppressive agents, cyclophosphamide or rituximab, in combination with glucocorticoids, and (2) remission maintenance with less potent immunosuppressive agents, such as azathioprine or methotrexate. Current standard of care treatment regimens are fraught with morbidities associated with most immunosuppressive agents, namely opportunistic infections [5, 6] .
BK virus (BKV) is a human polyomavirus that has emerged as an important cause of renal dysfunction in kidney transplant (KTX) recipients with graft loss in 10-50% of patients with BKV nephropathy [7] and rare reports of specific malignancies in renal transplant recipients in the setting of detectable BKV replication [8] [9] [10] . The intensity of overall immunosuppression is a major risk factor for the reactivation of BKV in KTX recipients. Immunologic control of BKV replication can be achieved by reduction, elimination or switching of immunosuppressive agents. To prevent BKV-related adverse outcomes, current guidelines established by an international panel of transplant physicians recommend posttransplant screening for BKV replication in KTX recipients, every 3 months for the first 2 years and annually thereafter until the 5th year after transplantation [11] .
Patients with AAV and KTX have many of the same complications with BKV as those without AAV. Among 85 AAV patients who underwent KTX for ESRD, BKV nephropathy was reported in 6 of 85 KTX recipients [12] . Interestingly, individuals with AAV almost universally receive significant immunosuppression due to the nature of their disease, regardless if they are a KTX recipient or not. The prevalence of BKV replication in immunosuppressed AAV patients without KTX, many of whom receive immunosuppressive regimens, is not known. This may have important implications regarding future recommendations for BKV screening in this population.
Materials and Methods
The study protocol was approved by the Johns Hopkins University Institutional Review Board. Patients with a diagnosis of GPA or MPA followed at the Johns Hopkins Vasculitis Center from 2011 to 2012 without a history of KTX were recruited for this cross-sectional analysis (group A). Patients were clinically classified as GPA or MPA as defined by the Chapel Hill Consensus Conference [13] . All patients were required to be on immunosuppressive drug treatment for either induction or maintenance of remission of their vasculitis.
For comparison, we identified a historical cohort of GPA/MPA patients who had undergone KTX for ESRD between the years 1999 to 2011 from the Hopkins transplant vasculitis database. Patients in this cohort who underwent testing for BKV were identified (group B) and analyzed to compare the prevalence of BKV replication.
Acquisition of Clinical Data
Patient demographics, organ involvement at the time of diagnosis, AAV disease duration and details of immunosuppressive drug use were abstracted from the electronic medical record.
Laboratory Data
Peak serum creatinine at the time of diagnosis and serum creatinine at 12 months when available and serum creatinine at the time of BKV testing were recorded. Presence or absence of c-ANCA, p-ANCA, PR3 ELISA and MPO ELISA at the time of diagnosis was recorded. ANCA testing was done by standard indirect immunofluorescence assay on ethanol fixed neutrophils. PR3 and MPO testing was done by direct enzyme-linked immunosorbent assay with commercially available kits. ANCA titer of greater than 10 was considered to be positive for c-ANCA and p-ANCA (reference range 0-10 units). PR 3 and MPO levels of greater than 20 units (reference range 0-20 units) were positive. If the testing for c-ANCA, p-ANCA, PR3 ELISA and MPO ELISA was negative, patients were labeled as having ANCA-negative vasculitis.
Testing for BKV Replication and TaqMan Real-Time PCR Assay for BKV Detection and Quantitation
We looked for evidence of BKV replication in plasma using quantitative plasma BKV PCR assay at a single time point. The study subjects had blood (5 ml) collected at their routinely scheduled clinic visit. The serum and plasma were aliquotted into 0.5 ml amounts and stored at -80 ° C.
Evidence of BKV replication was obtained by quantitative realtime PCR of plasma. Two tests of record in the Johns Hopkins Medical Microbiology Laboratory were used to determine replication in the historical cohort. The first, based on amplification/detection of T antigen promoter sequences [14] , had a limit of detection of 200 copies/ml and was in place from October 2005 to August 2011. The second test, adopted in September 2011 and currently in clinical use, employs commercial primers and probe (artus/Qiagen, Gaithersburg, Md., USA) to amplify/detect an unspecified BKV genome region and has a limit of detection of 30 copies/ml. The second, more sensitive assay was also used to detect BKV replication in the prospective cohort of GPA and MPA patients who did not undergo KTX.
Statistical Analyses BKV replication prevalence was compared between the nontransplant GPA/MPA vasculitis cohort and the historical cohort of GPA/MPA vasculitis KTX recipients. Descriptive statistics were used to investigate the clinical characteristics of GPA/MPA patients with and without KTX. Continuous variables were expressed as mean value ± standard deviation. Discrete variables were expressed as proportions. Fisher's exact test of independence for 2 × 2 tables was used to detect group (transplanted, nontransplanted) differences in prevalence of BKV replication using frequency data (number of patients with BKV replication in plasma).
Results

Demographics and Clinical Characteristics of GPA/ MPA Patients without KTX (Group A)
Demographic and clinical characteristics of the 37 patients with GPA or MPA who participated in the study are shown in table 1 . The mean age was 57 (SD 16) years, females comprised 54% of patients, and the majority were Caucasian (92%). Disease phenotype was GPA in 25 patients and MPA in 12 patients. Thirty-six patients were ANCA positive (c-ANCA: 21, p-ANCA: 15). The mean disease duration was 75 months. Renal involvement was present in 224 (65%) of these patients with 17 having biopsy-proven glomerulonephritis.
The details of immunosuppressive drug therapy are listed in table 2 . The mean time from induction therapy to BKV testing was 36 months and 19 of 37 patients were tested within 24 months of induction therapy. At the time of BKV testing, 73% of patients were on a combination of prednisone (P) with azathioprine, mycophenolate mofetil (MMF), methotrexate or leflunomide. 27% were on P monotherapy.
Demographics and Clinical Characteristics of GPA/ MPA Patients with KTX (Group B)
Thirty-five GPA/MPA patients that had undergone KTX for ESRD due to AAV were identified from the Hopkins transplant vasculitis database. BKV surveillance testing with plasma BKV PCR was started at our institution in 2005. Fifteen patients transplanted between 2006 and 2011 underwent surveillance with quantitative plasma BKV testing every 3 months for the first year after transplant and every 6 months during the 2nd year after transplant with quantitative plasma BK PCR assay. In one additional patient, elevated serum creatinine prompted allograft biopsy and a quantitative plasma BKV PCR assay. The mean duration of vasculitis prior to transplant in these 16 patients was 76 months. The mean age of the 16 patients (8 males and 8 females) tested for BKV replication was 56 years. Disease phenotype was GPA in 8 patients and MPA in 8 patients. Fifteen patients received induction therapy (12 with anti-thymocyte globulin, 3 with interleukin 2 receptor antagonists (1 with daclizumab and 2 with basiliximab). Fifteen patients received P, MMF and tacrolimus for maintenance immunosuppression, while a single patient received sirolimus, MMF and P ( table 3 ) .
Prevalence of BKV replication
The prevalence of detectable BKV in plasma was different between the prospective non-KTX and historical KTX AAV cohorts ( table 4 ). None of the nontransplanted vasculitis patients had detectable BKV in plasma. However, 5/16 (31%) transplanted GPA/MPA patients had detectable BKV in plasma or allograft during surveillance or when tested to evaluate allograft dysfunction. Virus was detected at a mean of 15 months after KTX. The median viral load at first detectable viremia was 5,160 copies/ ml. The immunosuppressive regimen of the 5 transplanted patients with demonstrable BKV was maintenance therapy with MMF, P and tacrolimus. Four of the 5 patients received induction therapy (3: anti-thymocyte globulin, 1: basiliximab). All patients underwent reduction of immunosuppressive therapy after detection of viremia with stabilization of allograft function. Four patients cleared viremia at a median of 4.5 months and 1 patient had low-level viremia 14 months after KTX.
Discussion
This study failed to detect evidence of BKV viremia in immunosuppressed GPA/MPA patients without KTX and confirmed the prevalence of this virus in transplanted GPA/MPA patients. These findings are highly suggestive of important underlying differences between these two populations, the etiology of which remains unclear, but could include specific immunosuppressive agents, donor origin of BKV, alloimmune activation or differences in host defense mechanisms. The study limitations include small sample size and disproportional testing for BKV viremia in nontransplanted AAV patients (who were assayed at a single time point), compared to KTX AAV patients (who were assayed serially as part of surveillance screening).
Primary infection with BKV occurs in early childhood and is asymptomatic. The virus then remains latent in urothelium and renal tubular epithelial cells. Asymptomatic viral activation and low-level viruria can occur in 5% of healthy individuals. However, viral reactivation is more common after KTX with viruria in 30-60%, viremia in 21% and BKV nephropathy in 1-10% [11, 15] . The overall intensity of immunosuppression has been accepted as a risk factor for BKV replication in KTX recipients. Other proposed risk factors include viral tropism for urothelium, human leukocyte mismatches between the donor and recipient, immunosuppressive therapy and other unknown factors [15] . In KTX recipients, BKV viremia and nephropathy has been observed with various immunosuppressive regimens. However, a higher risk of BKV replication is observed with standard-dose tacrolimus than cyclosporine when combined with MMF and P [16, 17] . In KTX recipients, BKV-specific T cell responses in these patients have been shown to be inversely correlated with tacrolimus levels but not with P, mycophenolate levels or other immunosuppressive drugs [18] . Vasudev et al. [19] have shown that reduction of the calcineurin inhibitor score derived from a scaling system used for immunosuppressive dose reduction for BKV replication but not the overall reduction in unit immunosuppressive score correlated significantly with slowing allograft functional loss in patients with BKV nephropathy. Calcineurin inhibitors inhibit T cell activation, while the antiproliferative agents interfere with T cell proliferation. Additionally, T celldepleting antibody commonly used for induction therapy in KTX recipients has been shown to be an independent risk factor for BKV replication [20] . In addition to corticosteroids, the standard treatment regimens in AAV patients without KTX typically include remission induction therapy with cyclophosphamide and rituximab which are relatively B cell specific and remission maintenance therapy antiproliferative agents like azathioprine and MMF but do not include calcineurin inhibitors. These differences in immunosuppressive drug therapy may explain the absence of BKV replication in AAV patients without KTX.
BKV replication has been reported in other autoimmune diseases and in solid organ recipients other than KTX; however, the highest rates of viruria, viremia and nephropathy appear to occur in KTX recipients. A crosssectional prevalence study in lupus patients showed a high prevalence of BKV viruria but no detectable viremia [21] . Additionally, in one point prevalence study, BKV viruria was documented in 27, 26 and 8% of kidney, heart and liver transplant recipients, while BKV viremia was detected in 12 and 7% of kidney and heart transplant recipients, respectively [22] . The pathogenesis of enhanced BKV replication and associated nephropathy in KTX is unclear. Explanations include alloimmune activation in the renal allograft as has been shown in an animal model [23] and kidney damage [24] , although factors leading to kidney damage such as cold ischemia time, donor source, donor-recipient HLA matching and rejection episodes leading to kidney damage have not been consistently associated with disease [19, [25] [26] [27] . The observed difference in BKV replication between KTX recipients and other immunosuppressed patients may be due to differences in antiviral T cell immune responses. A study by Bohl et al. [28] provided evidence for donor source of BKV and also showed association of sustained BK viremia with lack of HLAC7 allele.
Disruption of the balance between the host immune response and BKV replication is almost certain to play a role. Impaired immune responses to BKV infection in KTX include decreased production of specific antibodies B cells, ineffective immune surveillance by T cells, and diminished dendritic cells [29] . Interestingly, AAV patients have been shown to have decreased dendritic cell numbers during active disease and in remission [30] . Despite this, we did not find any evidence of BKV replication in our immunosuppressed vasculitis patients. Finally, viral factors such as genomic rearrangements in noncoding control regions have been linked to increased replication in KTX recipients [31] .
This study is limited by small sample size. The assessment for BKV viremia occurred at a single time point in nontransplanted AAV patients compared to transplanted AAV patients subjected to BKV surveillance screening who were tested for BKV viremia at different time points. The mean time from induction therapy to testing in group A patients without KTX was 36 months. However, about 50% of patients were tested within 24 months of induction therapy, and all patients were on maintenance immunosuppression with majority of patients on combination therapy with two immunosuppressive drugs at the time of BKV testing. Since BKV replication in KTX recipients in linked to the intensity of immunosuppression, future studies aimed at testing for BKV replication immediately after the induction therapy as well as serial monitoring for BKV viremia in group A patients might give us a better estimate of BKV replication in this population. The diagnostic PCR assays for BKV are limited by lack of standardized assays. Although BK viruria occurs earlier than BK viremia, viruria was not tested in this study due to the low positive predictive value of viruria for BKV nephropathy and physiologic fluctuations in urinary BKV load.
This study is the only available study looking at prevalence of BKV replication in immunosuppressed AAV patients without a KTX. It contributes further to our understanding of BKV disease pathogenesis by providing data to support the hypothesis that factors in addition to immunosuppression may be important in replication and nephropathy in KTX.
